Knott David M Jr Sells 2,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Knott David M Jr trimmed its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 0.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 210,000 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. Catalyst Pharmaceuticals comprises 1.6% of Knott David M Jr’s investment portfolio, making the stock its 10th biggest holding. Knott David M Jr owned 0.18% of Catalyst Pharmaceuticals worth $4,383,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its holdings in shares of Catalyst Pharmaceuticals by 9.1% during the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after purchasing an additional 33,888 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 1,495 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 13.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company’s stock valued at $8,710,000 after acquiring an additional 50,888 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter worth about $1,185,000. Finally, Redhawk Wealth Advisors Inc. purchased a new position in Catalyst Pharmaceuticals during the fourth quarter worth about $1,273,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Trading Down 1.8 %

NASDAQ:CPRX opened at $24.25 on Tuesday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $26.16. The company has a market capitalization of $2.95 billion, a P/E ratio of 20.55, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. The firm has a 50-day moving average price of $22.69 and a two-hundred day moving average price of $21.86.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CPRX. Stephens reiterated an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Bank of America reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $32.29.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company’s stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.